Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRAS G12C Mutation

BACKGROUND: , locking it in its inactive state. CONCLUSIONS: -mutated NSCLC, adagrasib showed clinical efficacy without new safety signals.

⚡ This is an original paraphrased summary — not copied from the abstract. Full paper available at the source link below.

• 1 Adagrasib showed clinical activity and had an acceptable adverse-event profile in the phase 1-1b part of the KRYSTAL-1 phase 1-2 study.
• 2 METHODS: -mutated non-small-cell lung cancer (NSCLC) previously treated with platinum-based chemotherapy and anti-programmed death 1 or programmed death ligand 1 therapy.
• 3 The primary end point was objective response assessed by blinded independent central review.

Understanding this could lead to better treatments, improved diagnostics, or a deeper grasp of how the human body works — benefiting patient care globally.

This summary is based on publicly available metadata and abstract. For the full research paper, visit the original source: